In January, the U.S. Food and Drug Administration accepted Arrowhead Pharmaceuticals’ New Drug ... payment and $325 million through Sarepta stock. Price Action: ARWR stock is down 8.72% at ...

However, the stock was also likely negatively impacted by CNBC Mad Money host Jim Cramer's comments on Friday. He expressed reservations about buying shares of Recursion Pharmaceuticals in light ...

Rama covers the Healthcare sector, focusing on stocks such as Neurocrine, Oric Pharmaceuticals, and Day One Biopharmaceuticals. According to TipRanks, Rama has an average return of -0.8% and a 40. ...

JD.com, Eli Lilly and Company, Abbott Laboratories, Veeva Systems, and Johnson & Johnson are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool.

Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Here are four things you should know if you're thinking of buying Recursion Pharmaceuticals ...

Lexicon Pharmaceuticals LXRX has been analyzed by ... analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference ...

Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Vertex Pharmaceuticals fits this criterion perfectly. VRTX has a robust clinical pipeline of ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The generic pharmaceutical industry operates ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The generic pharmaceutical industry operates on ...

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Collegium Pharmaceutical, Inc. (NASDAQ:COLL) stands against ...

Small biotech stocks usually aren't a great fit for risk-averse investors. However, I think aggressive growth investors might want to consider buying Madrigal Pharmaceuticals' shares. Some ...